Immunotherapy plus chemotherapy before bladder cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 with good overall health (able to walk and do light activities)
- Bladder cancer confirmed by biopsy, advanced or high-risk type, and has not spread to other organs
- Fit enough to have bladder removal surgery and tolerate strong chemotherapy
- Good kidney, liver, heart, and bone marrow function based on recent blood tests
- No prior chemotherapy, immunotherapy, or other systemic cancer treatments for bladder cancer
- Willing to use effective birth control for 6 months after treatment (applies to women and men with female partners of childbearing age)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: vedisertib (a targeted therapy that attacks cancer cells with a certain protein) and toripalimab (an immunotherapy that helps your immune system fight cancer). The goal is to treat your bladder cancer while avoiding removal of the bladder.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) given before surgery can help patients with muscle-invasive bladder cancer or upper-tract urothelial cancer. The goal is to shrink tumors and improve outcomes before surgery removes the cancer.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
Hear when a new Muscle-Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.